Targeting CD22 for B-cell hematologic malignancies

Jia Xu; Wenjing Luo; Chenggong Li; Heng Mei

doi:10.1186/s40164-023-00454-7

Targeting CD22 for B-cell hematologic malignancies

Exp Hematol Oncol. 2023 Oct 11;12(1):90. doi: 10.1186/s40164-023-00454-7.

Authors

Jia Xu^{1

2}, Wenjing Luo^{1

2}, Chenggong Li^{3

4}, Heng Mei^{5

6}

Affiliations

¹ Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
² Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China.
³ Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China. [email protected].
⁴ Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China. [email protected].
⁵ Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China. [email protected].
⁶ Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China. [email protected].

Abstract

CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies. However, 30%-60% of patients eventually relapsed, with the CD19-negative relapse being an important hurdle to sustained remission. CD22 expression is independent of CD19 expression in malignant B cells. Consequently, CD22 is a potential alternative target for CD19 CAR-T cell-resistant patients. CD22-targeted therapies, mainly including the antibody-drug conjugates (ADCs) and CAR-T cells, have come into wide clinical use with acceptable toxicities and promising efficacy. In this review, we explore the molecular and physiological characteristics of CD22, development of CD22 ADCs and CAR-T cells, and the available clinical data on CD22 ADCs and CAR-T cell therapies. Furthermore, we propose some perspectives for overcoming tumor escape and enhancing the efficacy of CD22-targeted therapies.

Keywords: CD22; CD22 CAR-T cell therapy; CD22 antibody–drug conjugate; Combination therapies; Dual-targeting CAR-T cell.

Publication types

Review

Abstract

Publication types

Grants and funding